Business Context and Reporting Period
Spyre Therapeutics, Inc. (SYRE) filed a Form 8-K on May 29, 2026, reporting a material event regarding its intellectual property licensing. The company is a Delaware corporation headquartered in Waltham, MA, with common stock listed on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The primary material change is the execution of the First Amendment to the Amended and Restated License Agreement with Paragon Therapeutics, Inc. regarding the asset SPY003 (IL-23). Key changes include:
- Field Expansion: The definition of the "Field" was expanded from being limited to inflammatory bowel disease to encompass all therapeutic, prophylactic, palliative, and diagnostic uses.
- Dosing Restrictions: Despite the expansion, the Company is restricted from dosing human patients in clinical trials for indications outside of inflammatory bowel disease until specific dates:
- Combination therapy: Until June 1, 2028.
- Monotherapy: Until June 1, 2030.
- Change of Control Provision: If a material transaction or change of control occurs, remaining restrictions outside the initial field definition will terminate on June 1, 2028.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or a discussion of general risks. The primary contingency noted is the timeline for clinical dosing restrictions, which may impact the speed of development for non-inflammatory bowel disease indications. The full terms are qualified by reference to the attached Exhibit 10.1.
Investor Verification Checklist
- Verify the specific clinical development timeline for SPY003 outside of inflammatory bowel disease against the June 2028 (combination) and June 2030 (monotherapy) restrictions.
- Review the full text of the First Amendment (Exhibit 10.1) for any undisclosed financial terms, milestone payments, or royalty adjustments resulting from the field expansion.
- Assess the impact of the "Change of Control" clause on potential M&A activity, specifically the acceleration of rights termination to June 2028.
- Confirm the current status of Paragon Therapeutics, Inc. and its retained rights under the agreement.